Estimation of the low-density lipoprotein (LDL) subclass phenotype using a direct, automated assay of small dense LDL-cholesterol without sample pretreatment

Clinica Chimica Acta

Volumn 411, Issue 17-18, 2010, Pages 1361-1366

  Vandermeersch, Annemie ^a   Ameye, Sara ^a   Puype, Dieter ^a   Petitjean, Dominique ^a   De Buyzere, Marc ^b   Langlois, Michel R ^a,b  

^a General Hospital St Jan   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Apolipoprotein A I; Apolipoprotein B; LDL subclass phenotype; Non HDL cholesterol; Small dense LDL cholesterol; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANALYZER; ARTICLE; AUTOMATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTICLE SIZE; PHENOTYPE; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CLASSIFICATION; REPRODUCIBILITY;

ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; LIPOPROTEINS, LDL; REPRODUCIBILITY OF RESULTS; TRIGLYCERIDES;

NON-A, NON-B HEPATITIS VIRUS;

EID: 77954144902     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.05.038     Document Type: Article

References (30)

1. Austin M.A., King M.C., Vrazinan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506.
2. Berneis K.K., Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002, 43:1363-1379.
3. Lamarche B., Tchernof A., Moorjani A.S., et al. Small, dense LDL particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
4. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of LDL particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007, 49:547-553.
5. Carmena R., Duriez P., Fruchart J.-C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109(Suppl III):2-7.
6. Verhoye E., Langlois M. Circulating oxidized low-density lipoprotein: a biomarker of atherosclerosis and cardiovascular risk?. Clin Chem Lab Med 2009, 47:128-137. On behalf of the Asklepios investigators.
7. Hirano T., Ito Y., Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 2005, 12:67-72.
8. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982, 23:97-140.
9. Kulkarni K.R., Garber D.W., Jones M.K., Segrest J.P. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. J Lipid Res 1995, 36:2291-2302.
10. Otvos J.D., Jeyarajah E.J., Bennett W.D., Krauss R.M. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992, 38:1632-1638.
11. Hirano T., Ito Y., Saegusa H., Yoshino G. A novel simple method for quantification of small, dense LDL. J Lipid Res 2003, 44:2193-2201.
12. Hirano T., Ito Y., Koba S., et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004, 24:558-563.
13. Hoefner D.M., Hodel S.D., O'Brien J.F., et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001, 47:266-274.
14. Ensign W., Hill N., Heward C.B. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem 2006, 52:1722-1727.
15. Stein E.A. Are measurements of LDL particles ready for prime time?. Clin Chem 2006, 52:1643-1644.
16. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy - a review of the evidence. J Intern Med 2004, 255:188-205.
17. Contois J.H., McConnell J.P., Sethi A.A., et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Disease Working Group on Best Practices. Clin Chem 2009, 55:407-419.
18. Blake G.J., Otvos J.D., Rifae N., Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002, 106:1930-1937.
19. Capell W.H., Zambon A., Austin M.A., Brunzell J.D., Hokanson J.E. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. Arterioscler Thromb Vasc Biol 1996, 16:1040-1046.
20. Tsimihodimos V., Gazi I., Kostara C., Tselepis A.D., Elisaf M. Plasma lipoproteins and triacylglycerol are predictors of small, dense LDL particles. Lipids 2007, 42:403-409.
21. Klerkx A.H.E.M., El Harchaoui K., Van der Steeg W.A., et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 2006, 26:706-715.
22. Guerin M., Lassel T.S., Le Goff W., Farnier M., Chapman M.J. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 Particles. Arterioscler Thromb Vasc Biol 2000, 20:189-197.
23. Griffin B.A., Freedman D.J., Tait G.W., Thomson J., Caslake M.J., Packard C.J., Shepherd J. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small dense LDL to coronary heart disease risk. Atherosclerosis 1994, 106:241-253.
24. Packard C.J., Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997, 17:3542-3556.
25. Gazi I., Lourida E.S., Filippatos T., Tsimihodimos V., Elisaf M., Tselepis A.D. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005, 51:2264-2273.
26. Maruyama C., Imamura K., Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb 2003, 10:186-191.
27. Décary S., Dumont G., Lamarche B., et al. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects. Clin Biochem 2010, 43:401-406.
28. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009, 55:378-384. NACB LMPG Committee Members.
29. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. The Emerging Risk Factor Collaboration.
30. Sniderman A., Williams K., Cobbaert C. ApoB versus non-HDL-C: what to do when they disagree. Curr Atheroscler Rep 2009, 358-363.